TransMedics Group (NASDAQ:TMDX) Trading Down 6.1%

Shares of TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) fell 6.1% during trading on Wednesday . The stock traded as low as $87.56 and last traded at $87.65. 447,535 shares traded hands during trading, a decline of 34% from the average session volume of 681,154 shares. The stock had previously closed at $93.31.

Analysts Set New Price Targets

Several brokerages have recently commented on TMDX. Piper Sandler began coverage on shares of TransMedics Group in a research report on Thursday, March 28th. They set an "overweight" rating and a $95.00 price target on the stock. JPMorgan Chase & Co. increased their price target on shares of TransMedics Group from $87.00 to $105.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 27th. Morgan Stanley increased their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 28th. Finally, Oppenheimer raised their target price on shares of TransMedics Group from $92.00 to $105.00 and gave the stock an "outperform" rating in a report on Tuesday, February 27th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $102.00.

TransMedics Group Stock Down 5.8 %

The company has a debt-to-equity ratio of 3.69, a current ratio of 9.30 and a quick ratio of 8.49. The stock's fifty day simple moving average is $83.01 and its 200-day simple moving average is $72.77. The stock has a market cap of $2.87 billion, a P/E ratio of -112.09 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its earnings results on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.22. The firm had revenue of $81.20 million for the quarter, compared to analysts' expectations of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. TransMedics Group's revenue was up 158.6% on a year-over-year basis. During the same quarter last year, the company posted ($0.21) earnings per share. On average, research analysts anticipate that TransMedics Group, Inc. will post -0.14 earnings per share for the current year.

Insider Activity

In other news, CEO Waleed H. Hassanein sold 12,000 shares of TransMedics Group stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total transaction of $1,141,080.00. Following the sale, the chief executive officer now owns 74,087 shares of the company's stock, valued at $7,044,932.83. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, CEO Waleed H. Hassanein sold 12,000 shares of TransMedics Group stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total transaction of $1,141,080.00. Following the sale, the chief executive officer now owns 74,087 shares of the company's stock, valued at $7,044,932.83. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Tamer I. Khayal sold 15,512 shares of TransMedics Group stock in a transaction that occurred on Tuesday, April 9th. The shares were sold at an average price of $90.45, for a total value of $1,403,060.40. Following the sale, the insider now directly owns 25,185 shares in the company, valued at approximately $2,277,983.25. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 115,408 shares of company stock valued at $9,802,401. Insiders own 6.70% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. FMR LLC increased its stake in shares of TransMedics Group by 42.5% during the third quarter. FMR LLC now owns 4,714,870 shares of the company's stock valued at $258,139,000 after acquiring an additional 1,407,171 shares during the period. BlackRock Inc. increased its stake in shares of TransMedics Group by 2.4% during the second quarter. BlackRock Inc. now owns 2,309,393 shares of the company's stock valued at $193,943,000 after acquiring an additional 54,776 shares during the period. Vanguard Group Inc. increased its stake in shares of TransMedics Group by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company's stock valued at $147,214,000 after acquiring an additional 50,673 shares during the period. Eventide Asset Management LLC increased its stake in shares of TransMedics Group by 7.4% during the fourth quarter. Eventide Asset Management LLC now owns 994,240 shares of the company's stock valued at $78,475,000 after acquiring an additional 68,884 shares during the period. Finally, Summit Partners Public Asset Management LLC increased its stake in shares of TransMedics Group by 71.9% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 957,282 shares of the company's stock valued at $59,083,000 after acquiring an additional 400,255 shares during the period. Institutional investors and hedge funds own 99.67% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.